media – Page 545 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors;

Denali Therapeutics Inc. (NASDAQ:DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced that it has commenced dosing of its small molecule inhibitor of RIPK1 in a Phase 1 clinical trial in healthy volunteers and achieved proof of concept of its large molecule blood-brain barrier delivery platform technology in nonhuman primates.
- Source: Nasdaq
- 560
- March 21, 2018
Clinical Trial neurodegenerative disease RIPK1
Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance its Topical and Systemic RORt Therapies for Psoriasis and other Autoimmune Diseases

Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
- Source: biotech-365
- 754
- March 21, 2018
autoimmune Company Insight financing psoriasis
NHS and digital health firms must improve cybersecurity

The NHS and digital health companies must learn from other industries to secure devices and systems against cyber attacks, according to a new report.
- Source: PharmaPhorum
- 696
- March 21, 2018
cybersecurity NHS Policies
Dova Pharmaceuticals Signs Exclusive Distribution Agreement with Fosun Pharma For Mainland China and Hong Kong

Dova Pharmaceuticals, Inc. (DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, entered into an agreement through its wholly owned subsidiary, AkaRx, Inc., granting Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., (Fosun Pharma Industrial), a wholly owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) (SHA:600196) (HKG:02196), the exclusive development and distribution rights of avatrombopag in mainland China and Hong Kong.
- Source: finance.yahoo
- 647
- March 21, 2018
avatrombopag Company Insight rare diseases
Insilico Medicine to launch R&D center and announce new research results in Taiwan ROC

Tuesday, March 20th, 2018, Insilico Medicine, a Baltimore-based artificial intelligence company specializing in drug discovery, biomarker development and aging research announced the launch of Insilico Taiwan, a subsidiary focusing on the development and validation of generative adversarial networks(GANs) and reinforcement learning for medicinal chemistry applications.
- Source: EurekAlert
- 582
- March 21, 2018
AI biomarker Company Insight Researches
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.
- Source: prnewswire
- 697
- March 21, 2018
aging Market Views Series
DocDoc raises US$5.45mil in Series B funding round

Singapore-based DocDoc, an Asian patient empowerment company, announced on March 19 that it has raised US$5.45 million (RM21.33 million) in their Series B round of funding.
- Source: Digital News Asia
- 609
- March 21, 2018
AI Company Insight healthcare
Bayer receives approval in China for Stivarga® (regorafenib) for the second-line systemic Treatment of liver cancer (for specialized target groups only)

Bayer reported that the Chinese Food and Drug Administration (CFDA) approved Stivarga (regorafenib) tablets for the second-line treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar (sorafenib) (Press release, Bayer, DEC 13, 2017, View Source [SID1234522618]).
- Source: 1stoncology
- 534
- March 20, 2018
HCC New Approvals Nexavar® Stivarga®
Adaptimmune’s GSK-partnered T cells trigger responses in solid tumor patients

Adaptimmune has seen partial responses in three of the first four myxoid/round cell liposarcoma (MRCLS) patients treated with its T cells. The early data raised hopes the GlaxoSmithKline-partnered drug will be effective in multiple types of solid tumor, sending Adaptimmune shares up nearly 20%.
- Source: Fiercebiotech
- 553
- March 20, 2018
Clinical Trials MRCLS solid tumor
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal

In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
- Source: pharmalive
- 562
- March 20, 2018
Akcea-TTR-LRx GlaxoSmithKline Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.